Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mark Lovell
University of Kentucky, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Fawkes Biotechnology, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Drs. Mark Lovell and colleagues developed an antibody-based test, similar in appearance to a pregnancy test, which provides an indication of the presence of and, by virtue of intensity, the severity of brain damage. The three investigators started Fawkes Biotechnology, LLC. Fawkes Biotechnology licensed from UK the “methods and systems for prognosis and diagnosis of brain damage”. The current study is a clinical study evaluating the technology in student-athletes.
Validation of a Point of Care Diagnostic Test for Sports Related Concussion
Narrative Mild traumatic brain injury (mTBI) resulting from sports related concussion (SRC) is a substantial public health concern with ~ 1.6 ? 3.8 million injuries per year in the United States. Despite considerable research there remains a critical need for a point of care test that can rapidly measure a maker of injury in blood on the playing field during a clinically useful time frame. Preliminary and future studies described in this proposal aim to test the usefulness of a lateral flow device (LFD) that quantifies a specific post-translational modification of visinin like protein 1 (VILIP-1), a neuron specific Ca2+-sensor protein released into blood following mTBI as an objective marker of SRC. �
Filed on April 15, 2019.
Tell us what you know about Mark Lovell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Mark Lovell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Mark Lovell | University of Kentucky | Conflict of Interest | Fawkes Biotechnology, LLC | Value cannot be readily determined |
Other search results for: “Mark Lovell”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Mark Lovell | University of Kentucky | Financial Disclosure |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.